A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 130 participants.

Also called NCT06925750

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06925750
  • EU CT 2024-518687-12-00
  • WHO UTN U1111-1314-0614
  • jRCT jRCT2061250021
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Canada, China, Colombia, Czechia, France, Hungary, Israel, Italy, Japan, Netherlands, Singapore, South Korea, Spain, Taiwan, Thailand, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06925750. Allocation not applicable; no masking; primary purpose treatment. Start 2025-05-12 (actual); primary completion 2028-06-16 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
Acronym
LIGHTRAY EXT
Condition
Pulmonary Arterial Hypertension
Intervention (Biological)
Sotatercept
Intervention (Drug)
Background PAH Therapy
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct06925750
Content hash
e4c97f8d85290224d01df14b739affd809f8994e8dcf3c13e6111967a7d6d1a3